Literature DB >> 16436646

Detection of an apparent homozygous 3120G>A cystic fibrosis mutation on a routine carrier screen.

Denise LaMarche Heaney1, Patrick Flume, Lauren Hamilton, Elaine Lyon, Daynna J Wolff.   

Abstract

A 28-year-old Caucasian female with no personal or family history of cystic fibrosis (CF) presented for preconception counseling and screening. Cystic fibrosis transmembrane conductance regulator (CFTR) mutation analysis using the Inno-LiPa CFTR assay revealed lack of hybridization for both the wild-type and mutant oligonucleotides for 3120+1G>A. This region was sequenced, and an apparent homozygous 3120G>A mutation was detected. Additional testing revealed an abnormal sweat chloride (77 mmol/L). Review of systems was essentially unremarkable with an absence of sinus symptoms, occasional nonproductive cough, and no features of malabsorption. Physical examination, chest X-ray, and pulmonary function tests were within normal limits. Only two other patients (siblings) with homozygous 3120G>A mutations have been reported (http://www.genet.sickkids.on.ca/cftr/). Both siblings had pancreatic insufficiency, mild pulmonary symptoms, and abnormal sweat chloride levels. Our findings suggest that a homozygous mutation of a G>A conversion at 3120 is associated with abnormal CFTR function and either a mild form of CF or no overt symptoms of disease, emphasizing the difficulties in assigning genotype/phenotype correlation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16436646      PMCID: PMC1867569          DOI: 10.2353/jmoldx.2006.050065

Source DB:  PubMed          Journal:  J Mol Diagn        ISSN: 1525-1578            Impact factor:   5.568


  19 in total

1.  Reaching the diagnosis of cystic fibrosis--the limits of the spectrum.

Authors:  Y Lotem; A Barak; H Mussaffi; M Shohat; M Wilschanski; Y Sivan; H Blau
Journal:  Isr Med Assoc J       Date:  2000-02       Impact factor: 0.892

Review 2.  Genetic testing for cystic fibrosis. National Institutes of Health Consensus Development Conference Statement on genetic testing for cystic fibrosis.

Authors: 
Journal:  Arch Intern Med       Date:  1999-07-26

3.  Cystic fibrosis screening: lessons learned from the first 320,000 patients.

Authors:  Charles M Strom; Beryl Crossley; Joy B Redman; Arlene Buller; Franklin Quan; Mei Peng; Matthew McGinnis; Weimin Sun
Journal:  Genet Med       Date:  2004 May-Jun       Impact factor: 8.822

4.  Identification of the cystic fibrosis gene: chromosome walking and jumping.

Authors:  J M Rommens; M C Iannuzzi; B Kerem; M L Drumm; G Melmer; M Dean; R Rozmahel; J L Cole; D Kennedy; N Hidaka
Journal:  Science       Date:  1989-09-08       Impact factor: 47.728

5.  Uniparental disomy as a mechanism for human genetic disease.

Authors:  J E Spence; R G Perciaccante; G M Greig; H F Willard; D H Ledbetter; J F Hejtmancik; M S Pollack; W E O'Brien; A L Beaudet
Journal:  Am J Hum Genet       Date:  1988-02       Impact factor: 11.025

6.  Genomic rearrangements in the CFTR gene: extensive allelic heterogeneity and diverse mutational mechanisms.

Authors:  Marie-Pierre Audrézet; Jian-Min Chen; Odile Raguénès; Nadia Chuzhanova; Karine Giteau; Cédric Le Maréchal; Isabelle Quéré; David N Cooper; Claude Férec
Journal:  Hum Mutat       Date:  2004-04       Impact factor: 4.878

7.  Updated assessment of cystic fibrosis mutation frequencies in non-Hispanic Caucasians.

Authors:  Glenn E Palomaki; James E Haddow; Linda A Bradley; Stacey C FitzSimmons
Journal:  Genet Med       Date:  2002 Mar-Apr       Impact factor: 8.822

8.  Cystic fibrosis screening using the College panel: platform comparison and lessons learned from the first 20,000 samples.

Authors:  Charles M Strom; Donghui Huang; Arlene Buller; Joy Redman; Beryl Crossley; Ben Anderson; Tom Entwistle; Weimin Sun
Journal:  Genet Med       Date:  2002 Jul-Aug       Impact factor: 8.822

9.  Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel.

Authors:  Michael S Watson; Garry R Cutting; Robert J Desnick; Deborah A Driscoll; Katherine Klinger; Michael Mennuti; Glenn E Palomaki; Bradley W Popovich; Victoria M Pratt; Elizabeth M Rohlfs; Charles M Strom; C Sue Richards; David R Witt; Wayne W Grody
Journal:  Genet Med       Date:  2004 Sep-Oct       Impact factor: 8.822

10.  The I148T CFTR allele occurs on multiple haplotypes: a complex allele is associated with cystic fibrosis.

Authors:  Elizabeth M Rohlfs; Zhaoqing Zhou; Elaine A Sugarman; Ruth A Heim; Rhonda G Pace; Michael R Knowles; Lawrence M Silverman; Bernice A Allitto
Journal:  Genet Med       Date:  2002 Sep-Oct       Impact factor: 8.822

View more
  4 in total

1.  Identification of cystic fibrosis variants by polymerase chain reaction/oligonucleotide ligation assay.

Authors:  Karen M Schwartz; Lisa L Pike-Buchanan; Kasinathan Muralidharan; Joy B Redman; Jean Amos Wilson; Michael Jarvis; M Grace Cura; Victoria M Pratt
Journal:  J Mol Diagn       Date:  2009-03-26       Impact factor: 5.568

2.  Assessment of Correlation between Sweat Chloride Levels and Clinical Features of Cystic Fibrosis Patients.

Authors:  Manzoor A Raina; Mosin S Khan; Showkat A Malik; Ab Hameed Raina; Mudassir J Makhdoomi; Javed I Bhat; Syed Mudassar
Journal:  J Clin Diagn Res       Date:  2016-12-01

3.  A deep learning approach to identify gene targets of a therapeutic for human splicing disorders.

Authors:  Dadi Gao; Elisabetta Morini; Monica Salani; Aram J Krauson; Anil Chekuri; Neeraj Sharma; Ashok Ragavendran; Serkan Erdin; Emily M Logan; Wencheng Li; Amal Dakka; Jana Narasimhan; Xin Zhao; Nikolai Naryshkin; Christopher R Trotta; Kerstin A Effenberger; Matthew G Woll; Vijayalakshmi Gabbeta; Gary Karp; Yong Yu; Graham Johnson; William D Paquette; Garry R Cutting; Michael E Talkowski; Susan A Slaugenhaupt
Journal:  Nat Commun       Date:  2021-06-07       Impact factor: 14.919

4.  CFTR mutations spectrum and the efficiency of molecular diagnostics in Polish cystic fibrosis patients.

Authors:  Ewa Ziętkiewicz; Ewa Rutkiewicz; Andrzej Pogorzelski; Barbara Klimek; Katarzyna Voelkel; Michał Witt
Journal:  PLoS One       Date:  2014-02-26       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.